Genotype-Phenotype of CRB1-Associated Early-Onset Retinal Dystrophy: Novel Insights on Retinal Architecture and Therapeutic Window for Clinical Trials.

Authors:
Jin Y; Li S; Jiang Z; Sun L; Huang L and 3 more

Journal:
Invest Ophthalmol Vis Sci

Publication Year: 2024

DOI:
10.1167/iovs.65.3.11

PMCID:
PMC10929744

PMID:
38466290

Journal Information

Journal Title: Invest Ophthalmol Vis Sci

Detailed journal information not available.

Publication Details

Subject Category: Ophthalmology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Author Contributors: Yili Jin, Songshan Li, and Xiaoyan Ding performed the bioinformatic analysis and design the study. Yili Jin, Songshan Li, Zhaoxin Jiang, Ting Zhang, Li Huang, Limei Sun, and Xiaoyan Ding recruited the individuals diagnosed with different forms of eye conditions. Yili Jin collected the clinical records. Songshan Li and Yili Jin confirmed the variants by Sanger sequencing and did the statistical analysis of clinical data. Yili Jin, Songshan Li, and Xiaoyan Ding discussed the results and wrote the manuscript. All authors reviewed and approved the manuscript. The authors declare that there are no conflicts of interest regarding the publication of this article. Disclosure: Y. Jin, None; S. Li, None; Z. Jiang, None; L. Sun, None; L. Huang, None; T. Zhang, None; X. Liu, None; X. Ding, None"

Evidence found in paper:

"Supported by grants from the Construction Project of High-Level Hospitals in Guangdong Province (303020107, 303010303058); the National Natural Science Foundation of China (82271092); Guangdong Basic and Applied Basic Research Foundation (2023A1515010430)."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025